Table 2. Characteristic of 10 cancer patients positive for COVID-19.
AZ: azithromycin, BP: bilateral pneumonia, CT: computed tomography, iCHE: infusional chemotherapy, oCHE: oral chemotherapy, D/C: darunavir/cobicistat, HCQ: hydroxychloroquine, HT: hormone therapy, IM: immunoterapy, NP: no pneumonia, SC: supportive care, UP: unilateral pneumonia
| Patient | Age (years) | Sex | Site of cancer/stage | Cancer therapy | COVID-19 therapy | CT scan | Outcome |
| 01 | 69 | f | Colon/IV | iCHE | HCQ + AZ | BP | alive |
| 02 | 65 | m | Prostate/IV | iCHE | HCQ | BP | alive |
| 03 | 64 | m | Lung/IV | IM | HCQ+ D/C + AZ | BP | alive |
| 04 | 69 | m | Prostate/I | HT | HCQ | UP | alive |
| 05 | 76 | m | Biliary tract/IV | oCHE | HCQ+ D/C + AZ | BP | alive |
| 06 | 74 | m | Biliary tract/IV | iCHE | HCQ + AZ | BP | alive |
| 07 | 80 | m | Colon/IV | SC | no | NP | alive |
| 08 | 54 | m | Neuroendocrine pancreatic cancer/IV | iCHE | HCQ+ D/C + AZ+augmentin | UP | alive |
| 09 | 64 | f | Gastric/IV | SC | HCQ+ D/C + AZ+ enoxaparina | BP | alive |
| 10 | 77 | m | Lung/IV | iCHE | piperacilina/tazobactam + HCQ+ enoxaparina | BP | alive |